The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,296.00
Bid: 12,322.00
Ask: 12,324.00
Change: -108.00 (-0.87%)
Spread: 2.00 (0.016%)
Open: 12,334.00
High: 12,362.00
Low: 12,250.00
Prev. Close: 12,404.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London close: Stocks end with modest gain, but down on week overall

Fri, 26th Sep 2014 16:48

UK stocks ended the final session of the week with a modest rise, although on the week the index was significantly lower.The FTSE 100 closed 9.68 points higher at 6,649.39.Markets are concerned about mounting geopolitical tensions, with the government due to take a vote on whether to participate in a war against the "Islamic State" on Friday evening.David Cameron and Ed Miliband took to the stands in the House of Commons on Friday morning in an attempt to persuade parliament to support airstrikes against Islamic State (IS) militants in Iraq.Cameron urged members to support military action in the region, underlining Britain's clear basis for action in international law, strengthened by a direct request for British intervention made by the Iraqi government.The Prime Minister also highlighted the international coalition's need for Britain's unique military and intelligence capabilities in order to fight the Islamist militant group."Is there a threat to the British people? The answer is yes," Cameron told parliament, saying he thought action would need to last "years" to be effective.Members are expected to vote in favour of entering the conflict.Soaring house prices could drive workers away from LondonLondon could be waving goodbye to a number of workers in the future, as the struggle to meet living costs in the British capital continues to rise.London's housing shortage could put the city's future at risk unless swift actions are taken to address one of the capital's chronic problems, research conducted by YouGov shows.Japanese CPI disappointsLooking abroad, Japanese consumer price inflation came in weaker than expected for August. The headline inflation rate slowed to a 3.3% year-on-year pace from 3.4%, with the ex-fresh food measure down to 3.1% from 3.3% (consensus: 3.2%)."Softer Japanese CPI data reinforced fears of more BoJ easing and hurt the JPY," analysts at UnicreditResearch said.Over in the States, gross domestic product (GDP) was revised higher in the second quarter, supported by better retail sales and foreign trade numbers.The US economy grew at a 4.6% annual rate in the three months to end of June, as predicted by analysts.Easyjet shares take off thanks to comments from JefferiesShares in Easyjet flew higher after Jefferies said the airline was situated to benefit from the recent problems with Air France-KLM, which has been forced to cancel numerous flights due to pilot strike action. The broker also predicted the group would have a positive finish to the year.Astrazeneca shares also squeezed higher after the company received positive feedback for Moventig, its new treatment for opioid-induced constipation.British Land shares were lifted by Societe Generale after it lifted its rating from 'hold' to 'buy'.Meanwhile, Sports Direct shares slumped into the red one day after its boss, Mike Ashley, yesterday surprised the market with the news it has completed a "put" option with Goldman Sachs in a complicated move that it said "reflects Sports Direct's growing relationship with Tesco and belief in Tesco's long-term future". The option relates to 23m Tesco shares.Tesco, together with its sector peers Sainsbury and Morrison, all continued to decline amid the growing price war amongst supermarkets.Slower-than-expected growth in its solutions division and challenging market conditions in its currency division have forced security documents designer and producer De La Rue to issue a profit warning, sending shares sharply lower.The FTSE 250 company said it expects operating profit and underlying profit before tax for the year to be £20m lower than originally estimated.Market MoverstechMARK 2,810.43 +0.37%FTSE 100 6,649.39 +0.15%FTSE 250 15,383.69 -0.27%FTSE 100 - RiserseasyJet (EZJ) 1,393.00p +3.19%St James's Place (STJ) 739.00p +2.78%British Land Co (BLND) 706.00p +2.10%Fresnillo (FRES) 761.50p +1.80%Shire Plc (SHP) 5,330.00p +1.72%ARM Holdings (ARM) 919.00p +1.66%Admiral Group (ADM) 1,253.00p +1.62%International Consolidated Airlines Group SA (CDI) (IAG) 370.70p +1.51%Hammerson (HMSO) 571.50p +1.51%Intu Properties (INTU) 330.50p +1.47%FTSE 100 - FallersSainsbury (J) (SBRY) 250.10p -3.06%Sports Direct International (SPD) 620.50p -2.67%Morrison (Wm) Supermarkets (MRW) 171.00p -1.78%Imperial Tobacco Group (IMT) 2,647.00p -1.78%IMI (IMI) 1,244.00p -1.66%Petrofac Ltd. (PFC) 1,010.00p -1.08%CRH (CRH) 1,389.00p -1.00%BG Group (BG.) 1,127.50p -0.97%TUI Travel (TT.) 387.50p -0.95%3i Group (III) 384.60p -0.88%FTSE 250 - RisersSupergroup (SGP) 1,136.00p +4.22%Fidessa Group (FDSA) 2,303.00p +3.00%Betfair Group (BET) 1,172.00p +2.99%Pets at Home Group (PETS) 176.00p +2.92%Evraz (EVR) 127.10p +2.92%Zoopla Property Group (WI) (ZPLA) 234.90p +2.76%SEGRO (SGRO) 365.40p +2.50%Millennium & Copthorne Hotels (MLC) 556.00p +2.39%Balfour Beatty (BBY) 224.90p +2.13%Capital & Counties Properties (CAPC) 332.40p +2.03%FTSE 250 - FallersDe La Rue (DLAR) 504.00p -33.60%Greencore Group (GNC) 240.80p -4.82%Ocado Group (OCDO) 267.40p -3.67%Daejan Holdings (DJAN) 4,878.00p -3.31%Hochschild Mining (HOC) 139.70p -2.92%Vesuvius (VSVS) 452.50p -2.88%Synthomer (SYNT) 215.00p -2.80%Playtech (PTEC) 716.00p -2.78%African Barrick Gold (ABG) 207.50p -2.72%Soco International (SIA) 372.40p -2.69%
More News
17 Nov 2023 09:03

LONDON MARKET OPEN: Stocks up despite UK retail sales growth miss

(Alliance News) - Stock prices in London opened higher on Friday, despite weaker-than-expected October retail sales figures for the UK.

Read more
17 Nov 2023 08:31

TOP NEWS: US approves AstraZeneca's Truqap for form of breast cancer

(Alliance News) - AstraZeneca PLC on Friday said that the US Food & Drug Administration approved its drug Truqap in combination with Faslodex to treat patients with an advanced form of breast cancer.

Read more
17 Nov 2023 07:58

LONDON BRIEFING: UK retail sales fall; AstraZeneca gets US approval

(Alliance News) - Stock prices in London are still set to open higher on Friday, despite October retail sales figures for the UK disappointing shortly before the opening bell.

Read more
17 Nov 2023 07:16

AstraZeneca gets US approval for breast cancer treatment

(Sharecast News) - AstraZeneca's 'Truqap', or capivasertib, in combination with 'Faslodex', or fulvestrant, has secured approval from the US Food and Drug Administration (FDA) for specific breast cancer treatments, the company announced on Friday.

Read more
14 Nov 2023 10:51

TOP NEWS: AstraZeneca Imfinzi fails to meet endpoint in cancer trial

(Alliance News) - AstraZeneca PLC on Tuesday said the Pacific-2 phase III trial for Imfinzi as an early treatment lung cancer immunotherapy treatment administered with chemoradiotherapy, did not meet its primary endpoint.

Read more
14 Nov 2023 09:22

AstraZeneca's latest lung cancer trial fails its primary endpoint

(Sharecast News) - AstraZeneca announced on Tuesday that its 'PACIFIC-2' phase three trial for Imfinzi, or durvalumab, concurrently administered with chemoradiotherapy (CRT), did not achieve its primary endpoint of progression-free survival compared to CRT alone.

Read more
13 Nov 2023 09:45

LONDON BROKER RATINGS: Diageo gets price target cuts; JPMorgan ups M&G

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:

Read more
9 Nov 2023 15:02

London close: Stocks gain as investors await Powell speech

(Sharecast News) - London's stock markets were buoyant at the close of trading on Thursday, influenced by Chinese inflation data, a substantial influx of corporate news, and a speech from the Fed chair later in the global day.

Read more
9 Nov 2023 12:06

LONDON MARKET MIDDAY: FTSE up despite higher for longer US rates fear

(Alliance News) - European equities were on the up on Thursday, despite lingering US interest rate worries and poor China data.

Read more
9 Nov 2023 11:02

Lancashire Holdings declares special dividend after strong year so far

(Alliance News) - Lancashire Holdings Ltd on Thursday said it approved a capital return of up to USD169 million, and it reported rising gross premiums written for the year-to-date.

Read more
9 Nov 2023 09:23

TOP NEWS: AstraZeneca ups guidance; inks licence deal for obesity drug

(Alliance News) - AstraZeneca PLC on Thursday announced that it signed a contract for an obesity drug as it reported a higher pretax profit in the third quarter of 2023, boosted by cancer drug conjugate Enhertu.

Read more
9 Nov 2023 08:57

LONDON MARKET OPEN: FTSE 100 kicks off day with cautious gain

(Alliance News) - London's FTSE 100 struggled for direction early Thursday, with a mixed slate of corporate updates, US interest rate worries and underwhelming China data preventing it from making more confident progress in early trade.

Read more
9 Nov 2023 07:48

LONDON BRIEFING: AstraZeneca ups outlook but S4 Capital cuts

(Alliance News) - London's FTSE 100 is set for another downbeat start to the day, with more hawkish comments from US central bankers and tepid data out of China doing little to lift the mood.

Read more
9 Nov 2023 07:18

AstraZeneca hikes guidance after strong third quarter

(Sharecast News) - AstraZeneca released its financial results for the third quarter and first nine months of 2023 on Thursday, hiking its full-year guidance on the back of a robust performance and momentum in several segments.

Read more
3 Nov 2023 17:06

AstraZeneca plans next phase of trial on kidney drug combination data

(Alliance News) - AstraZeneca PLC on Friday touted results from a Phase IIb trial, which showed that a zibotentan and dapagliflozin combination demonstrated significant albuminuria reduction in patients with chronic kidney disease and proteinuria.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.